NCT03951051View on ClinicalTrials.gov

The Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil After a Single Oral Dose Administration Under Fasting Conditions.

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

May 6, 2019

Primary Completion Date

June 16, 2019

Study Completion Date

June 16, 2019

Conditions
Bioequivalence
Interventions
DRUG

Olmesartan Medoxomil 40 mg

Olmesartan Medoxomil is manufactured by Pharmtechnology LLC, Republic of Belarus. Each film-coated tablet contains 40 mg of olmesartan medoxomil.

DRUG

Olmetec®

Olmetec® is manufactured by Daiichi Sankyo Europe GmbH, Germany. Each film-coated tablet contains 40 mg of olmesartan medoxomil.

Trial Locations (1)

H3P 3P1

Altasciences Company Inc., Mount Royal

All Listed Sponsors
collaborator

Altasciences Company Inc.

INDUSTRY

lead

Pharmtechnology LLC

INDUSTRY

NCT03951051 - The Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil After a Single Oral Dose Administration Under Fasting Conditions. | Biotech Hunter | Biotech Hunter